Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
55
CRDL Quote, Financials, Valuation and Earnings
Last price:
$1.02
Seasonality move
:
14.38%
Day range:
$0.95 - $1.06
52-week range:
$0.77 - $1.59
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
15.28x
Volume:
779.2K
Avg. volume:
562.2K
1-year change:
-27.08%
Market cap:
$105M
Revenue:
--
EPS (TTM):
-$0.30
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CRDL
Cardiol Therapeutics, Inc.
|
-- | -$0.08 | -- | -9.21% | $7.86 |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$67.7M | $0.16 | 25.05% | 2133.71% | $16.67 |
|
EDSA
Edesa Biotech, Inc.
|
-- | -- | -- | -- | $10.33 |
|
LEXX
Lexaria Bioscience Corp.
|
$50K | -- | 63.1% | -- | $6.00 |
|
ONCY
Oncolytics Biotech, Inc.
|
-- | -$0.05 | -- | -15.25% | $5.49 |
|
XENE
Xenon Pharmaceuticals, Inc.
|
-- | -$1.13 | -- | -43.57% | $55.19 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CRDL
Cardiol Therapeutics, Inc.
|
$1.05 | $7.86 | $105M | -- | $0.00 | 0% | -- |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$15.62 | $16.67 | $2.1B | 27.84x | $0.00 | 0% | 8.29x |
|
EDSA
Edesa Biotech, Inc.
|
$1.76 | $10.33 | $12.4M | -- | $0.00 | 0% | 31.22x |
|
LEXX
Lexaria Bioscience Corp.
|
$1.06 | $6.00 | $23.6M | -- | $0.00 | 0% | 27.04x |
|
ONCY
Oncolytics Biotech, Inc.
|
$0.99 | $5.49 | $105.3M | -- | $0.00 | 0% | -- |
|
XENE
Xenon Pharmaceuticals, Inc.
|
$45.01 | $55.19 | $3.5B | -- | $0.00 | 0% | 473.02x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CRDL
Cardiol Therapeutics, Inc.
|
1.38% | 2.619 | 0.1% | 3.54x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
17.62% | -0.123 | 5.37% | 5.02x |
|
EDSA
Edesa Biotech, Inc.
|
-- | -0.273 | -- | 18.80x |
|
LEXX
Lexaria Bioscience Corp.
|
2.06% | -1.067 | 0.6% | 3.11x |
|
ONCY
Oncolytics Biotech, Inc.
|
87.89% | 4.153 | 0.41% | 1.61x |
|
XENE
Xenon Pharmaceuticals, Inc.
|
1.47% | 0.195 | 0.27% | 12.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CRDL
Cardiol Therapeutics, Inc.
|
-$18.6K | -$7.4M | -233.98% | -236.38% | -- | -$5.1M |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$65.3M | $30.7M | 17.52% | 21.42% | 41.75% | $44.9M |
|
EDSA
Edesa Biotech, Inc.
|
-$25.8K | -$1.9M | -80.33% | -80.46% | -- | -$1.8M |
|
LEXX
Lexaria Bioscience Corp.
|
$152.6K | -$2.5M | -144.76% | -147.19% | -2155.4% | -$3.6M |
|
ONCY
Oncolytics Biotech, Inc.
|
-$67.5K | -$10M | -540.79% | -635.07% | -- | -$4.9M |
|
XENE
Xenon Pharmaceuticals, Inc.
|
-$641K | -$96.3M | -43.83% | -44.39% | -969.84% | -$72.7M |
Cardiol Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns CRDL or AUPH?
Aurinia Pharmaceuticals, Inc. has a net margin of -- compared to Cardiol Therapeutics, Inc.'s net margin of 42.95%. Cardiol Therapeutics, Inc.'s return on equity of -236.38% beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.
Company Gross Margin Earnings Per Share Invested Capital CRDLCardiol Therapeutics, Inc.-- -$0.09 $7M AUPHAurinia Pharmaceuticals, Inc.88.87% $0.23 $444M -
What do Analysts Say About CRDL or AUPH?
Cardiol Therapeutics, Inc. has a consensus price target of $7.86, signalling upside risk potential of 648.82%. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 6.7%. Given that Cardiol Therapeutics, Inc. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe Cardiol Therapeutics, Inc. is more attractive than Aurinia Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRDLCardiol Therapeutics, Inc.3 0 0 AUPHAurinia Pharmaceuticals, Inc.4 3 0 -
Is CRDL or AUPH More Risky?
Cardiol Therapeutics, Inc. has a beta of 1.126, which suggesting that the stock is 12.56% more volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.425, suggesting its more volatile than the S&P 500 by 42.546%.
-
Which is a Better Dividend Stock CRDL or AUPH?
Cardiol Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardiol Therapeutics, Inc. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRDL or AUPH?
Cardiol Therapeutics, Inc. quarterly revenues are --, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. Cardiol Therapeutics, Inc.'s net income of -$7.2M is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, Cardiol Therapeutics, Inc.'s price-to-earnings ratio is -- while Aurinia Pharmaceuticals, Inc.'s PE ratio is 27.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiol Therapeutics, Inc. is -- versus 8.29x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRDLCardiol Therapeutics, Inc.-- -- -- -$7.2M AUPHAurinia Pharmaceuticals, Inc.8.29x 27.84x $73.5M $31.6M
-
Which has Higher Returns CRDL or EDSA?
Edesa Biotech, Inc. has a net margin of -- compared to Cardiol Therapeutics, Inc.'s net margin of --. Cardiol Therapeutics, Inc.'s return on equity of -236.38% beat Edesa Biotech, Inc.'s return on equity of -80.46%.
Company Gross Margin Earnings Per Share Invested Capital CRDLCardiol Therapeutics, Inc.-- -$0.09 $7M EDSAEdesa Biotech, Inc.-- -$0.25 $14.1M -
What do Analysts Say About CRDL or EDSA?
Cardiol Therapeutics, Inc. has a consensus price target of $7.86, signalling upside risk potential of 648.82%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $10.33 which suggests that it could grow by 525%. Given that Cardiol Therapeutics, Inc. has higher upside potential than Edesa Biotech, Inc., analysts believe Cardiol Therapeutics, Inc. is more attractive than Edesa Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRDLCardiol Therapeutics, Inc.3 0 0 EDSAEdesa Biotech, Inc.1 0 0 -
Is CRDL or EDSA More Risky?
Cardiol Therapeutics, Inc. has a beta of 1.126, which suggesting that the stock is 12.56% more volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.204%.
-
Which is a Better Dividend Stock CRDL or EDSA?
Cardiol Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardiol Therapeutics, Inc. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRDL or EDSA?
Cardiol Therapeutics, Inc. quarterly revenues are --, which are smaller than Edesa Biotech, Inc. quarterly revenues of --. Cardiol Therapeutics, Inc.'s net income of -$7.2M is lower than Edesa Biotech, Inc.'s net income of -$1.7M. Notably, Cardiol Therapeutics, Inc.'s price-to-earnings ratio is -- while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiol Therapeutics, Inc. is -- versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRDLCardiol Therapeutics, Inc.-- -- -- -$7.2M EDSAEdesa Biotech, Inc.31.22x -- -- -$1.7M
-
Which has Higher Returns CRDL or LEXX?
Lexaria Bioscience Corp. has a net margin of -- compared to Cardiol Therapeutics, Inc.'s net margin of -2178.51%. Cardiol Therapeutics, Inc.'s return on equity of -236.38% beat Lexaria Bioscience Corp.'s return on equity of -147.19%.
Company Gross Margin Earnings Per Share Invested Capital CRDLCardiol Therapeutics, Inc.-- -$0.09 $7M LEXXLexaria Bioscience Corp.91.15% -$0.14 $5.3M -
What do Analysts Say About CRDL or LEXX?
Cardiol Therapeutics, Inc. has a consensus price target of $7.86, signalling upside risk potential of 648.82%. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $6.00 which suggests that it could grow by 403.14%. Given that Cardiol Therapeutics, Inc. has higher upside potential than Lexaria Bioscience Corp., analysts believe Cardiol Therapeutics, Inc. is more attractive than Lexaria Bioscience Corp..
Company Buy Ratings Hold Ratings Sell Ratings CRDLCardiol Therapeutics, Inc.3 0 0 LEXXLexaria Bioscience Corp.0 0 0 -
Is CRDL or LEXX More Risky?
Cardiol Therapeutics, Inc. has a beta of 1.126, which suggesting that the stock is 12.56% more volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.221%.
-
Which is a Better Dividend Stock CRDL or LEXX?
Cardiol Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardiol Therapeutics, Inc. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRDL or LEXX?
Cardiol Therapeutics, Inc. quarterly revenues are --, which are smaller than Lexaria Bioscience Corp. quarterly revenues of $174K. Cardiol Therapeutics, Inc.'s net income of -$7.2M is lower than Lexaria Bioscience Corp.'s net income of -$2.7M. Notably, Cardiol Therapeutics, Inc.'s price-to-earnings ratio is -- while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiol Therapeutics, Inc. is -- versus 27.04x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRDLCardiol Therapeutics, Inc.-- -- -- -$7.2M LEXXLexaria Bioscience Corp.27.04x -- $174K -$2.7M
-
Which has Higher Returns CRDL or ONCY?
Oncolytics Biotech, Inc. has a net margin of -- compared to Cardiol Therapeutics, Inc.'s net margin of --. Cardiol Therapeutics, Inc.'s return on equity of -236.38% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.
Company Gross Margin Earnings Per Share Invested Capital CRDLCardiol Therapeutics, Inc.-- -$0.09 $7M ONCYOncolytics Biotech, Inc.-- -$0.10 $682.8K -
What do Analysts Say About CRDL or ONCY?
Cardiol Therapeutics, Inc. has a consensus price target of $7.86, signalling upside risk potential of 648.82%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.49 which suggests that it could grow by 452.93%. Given that Cardiol Therapeutics, Inc. has higher upside potential than Oncolytics Biotech, Inc., analysts believe Cardiol Therapeutics, Inc. is more attractive than Oncolytics Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRDLCardiol Therapeutics, Inc.3 0 0 ONCYOncolytics Biotech, Inc.3 1 0 -
Is CRDL or ONCY More Risky?
Cardiol Therapeutics, Inc. has a beta of 1.126, which suggesting that the stock is 12.56% more volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.
-
Which is a Better Dividend Stock CRDL or ONCY?
Cardiol Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardiol Therapeutics, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRDL or ONCY?
Cardiol Therapeutics, Inc. quarterly revenues are --, which are smaller than Oncolytics Biotech, Inc. quarterly revenues of --. Cardiol Therapeutics, Inc.'s net income of -$7.2M is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Cardiol Therapeutics, Inc.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiol Therapeutics, Inc. is -- versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRDLCardiol Therapeutics, Inc.-- -- -- -$7.2M ONCYOncolytics Biotech, Inc.-- -- -- -$10.5M
-
Which has Higher Returns CRDL or XENE?
Xenon Pharmaceuticals, Inc. has a net margin of -- compared to Cardiol Therapeutics, Inc.'s net margin of -867.29%. Cardiol Therapeutics, Inc.'s return on equity of -236.38% beat Xenon Pharmaceuticals, Inc.'s return on equity of -44.39%.
Company Gross Margin Earnings Per Share Invested Capital CRDLCardiol Therapeutics, Inc.-- -$0.09 $7M XENEXenon Pharmaceuticals, Inc.-- -$1.15 $567.8M -
What do Analysts Say About CRDL or XENE?
Cardiol Therapeutics, Inc. has a consensus price target of $7.86, signalling upside risk potential of 648.82%. On the other hand Xenon Pharmaceuticals, Inc. has an analysts' consensus of $55.19 which suggests that it could grow by 22.62%. Given that Cardiol Therapeutics, Inc. has higher upside potential than Xenon Pharmaceuticals, Inc., analysts believe Cardiol Therapeutics, Inc. is more attractive than Xenon Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRDLCardiol Therapeutics, Inc.3 0 0 XENEXenon Pharmaceuticals, Inc.17 0 0 -
Is CRDL or XENE More Risky?
Cardiol Therapeutics, Inc. has a beta of 1.126, which suggesting that the stock is 12.56% more volatile than S&P 500. In comparison Xenon Pharmaceuticals, Inc. has a beta of 1.027, suggesting its more volatile than the S&P 500 by 2.689%.
-
Which is a Better Dividend Stock CRDL or XENE?
Cardiol Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardiol Therapeutics, Inc. pays -- of its earnings as a dividend. Xenon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRDL or XENE?
Cardiol Therapeutics, Inc. quarterly revenues are --, which are smaller than Xenon Pharmaceuticals, Inc. quarterly revenues of --. Cardiol Therapeutics, Inc.'s net income of -$7.2M is higher than Xenon Pharmaceuticals, Inc.'s net income of -$90.9M. Notably, Cardiol Therapeutics, Inc.'s price-to-earnings ratio is -- while Xenon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiol Therapeutics, Inc. is -- versus 473.02x for Xenon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRDLCardiol Therapeutics, Inc.-- -- -- -$7.2M XENEXenon Pharmaceuticals, Inc.473.02x -- -- -$90.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 67.45% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 10.86% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 5.22% over the past day.
